Successful rechallenge of immune checkpoint inhibitor after immune-related myocarditis, myositis, myasthenia gravis overlap syndrome (IM3OS)
European Journal of Cancer · 2026-08 · 244 · 116890
DOI: 10.1016/j.ejca.2026.116890 ↗Kurz gefasst
Leserbrief in der Zeitschrift European Journal of Cancer, 2026-08. Verfasst von Fanny Rezungles und 4 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine and Immunopathology Department, Toulouse University Hospital, Toulouse, France. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Internal Medicine and Immunopathology Department, Toulouse University Hospital, Toulouse, France.
- Oncoderrmatology Department - Medical Oncology, The Cancer University of Toulouse Oncopole, Toulouse, France.
- Pathology Department, Toulouse University Hospital, Toulouse, France.
- Internal Medicine and Immunopathology Department, Toulouse University Hospital, Toulouse, France. Electronic address: rivet.valerian@iuct-oncopole.fr.
Zitieren
APA
Rezungles, F., Sibaud, V., Volosov, T., Comont, T., & Rivet, V. (2026). Successful rechallenge of immune checkpoint inhibitor after immune-related myocarditis, myositis, myasthenia gravis overlap syndrome (IM3OS). European Journal of Cancer, 244, 116890. https://doi.org/10.1016/j.ejca.2026.116890
Vancouver
Rezungles F, Sibaud V, Volosov T, Comont T, Rivet V. Successful rechallenge of immune checkpoint inhibitor after immune-related myocarditis, myositis, myasthenia gravis overlap syndrome (IM3OS). European Journal of Cancer. 2026;244:116890. doi:10.1016/j.ejca.2026.116890
BibTeX
@article{Rezungles2026,
author = {Rezungles, Fanny and Sibaud, Vincent and Volosov, Thomas and Comont, Thibault and Rivet, Valérian},
title = {Successful rechallenge of immune checkpoint inhibitor after immune-related myocarditis, myositis, myasthenia gravis overlap syndrome (IM3OS)},
journal = {European Journal of Cancer},
year = {2026},
volume = {244},
pages = {116890},
doi = {10.1016/j.ejca.2026.116890}
}
EUVIMED